Answers are grounded in this paper and cite their sources.
Ovarian cancer is a leading cause of death in all gynecological cancers, as recurrence, drug resistance, and limited therapeutic options remain critical clinical challenges despite advances. Heat Shock Protein 90 (HSP90) is a molecular chaperone and validated as an attractive therapeutic target in cancer drug discovery, as it supports many oncoproteins that act as critical regulators of the cell cycle, apoptosis, and signalling pathways. In this current study, a computational pipeline was used to evaluate bioactive phytochemicals from Hemidesmus indicus (L.) R. Br. ex-Schult as potential HSP90 inhibitors relevant to ovarian cancer. Among 87 phytochemicals screened, rutin, isoquercetin, and indicine were prioritized based on receptor-based molecular docking, exhibiting favorable docking scores of −14.99, −13.17, and −11.73 kcal/mol, respectively, compared with −5.07 kcal/mol for the reference HSP90 inhibitor geldanamycin. The corresponding MM-GBSA binding free energies were −80.93, −74.61, and −77.47 kcal/mol for rutin, isoquercetin, and indicine, respectively, compared with −80.02 kcal/mol for geldanamycin. In silico ADMET analysis predicted comparatively favorable pharmacokinetic characteristics for isoquercetin and indicine, whereas rutin showed predicted physicochemical limitations that may require further optimization. The stability of the HSP90-ligand complexes was investigated by performing 100-ns molecular dynamics simulations (MDS) with stable and persistent behavior in RMSD, RMSF, radius of gyration, and hydrogen bond parameters across the entire simulation trajectory. Principal component analysis (PCA)-based free energy landscape (FEL) mapping demonstrated well-defined low-energy conformational states, and MM-PBSA calculations affirmed strong interactions with active-site residues. Together, these in silico findings suggest that rutin, isoquercetin, and indicine may represent promising candidate HSP90-targeting compounds from H. indicus for further experimental validation to evaluate their anticancer potential. In vitro studies targeting HSP90 binding and ATPase activity together with ovarian cancer cell line testing, followed by in vivo experiments, are needed to confirm their therapeutic efficacy and anticancer effects.
No takes yet. Share an insight, caveat, or question.
Sivaprakasam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: